002004 Winbond Pharmaceutical s market outlook

Winbond Pharmaceutical is one of the few independent R&D enterprises among domestic listed companies, and has been at the forefront of domestic counterparts in grasping Nobel Prize-winning new technologies ——— chiral pharmaceutical technologies. From the perspective of the company's grasp of the core technology of chiral pharmaceuticals and the number of patents, it is relatively leading among domestic listed companies and has special investment value.

Winbond has a number of products with published patents and chiral drug patents. These include: anti-allergic drug solutions containing levocetirizine; ** Pharmaceutical composition for psoriasis; Etoposide enteric-coated slow-release (controlled) release solid dispersion preparation and preparation method thereof; Stilbene derivatives organic amine salts and preparation methods, uses and pharmaceutical compositions, etc.

Among them, levocetirizine and calcium levofinate are the company's representative chiral new drugs, and the substitution effect on non-chiral drugs is very strong, and it is expected that the contribution rate of these two drugs to the company's performance growth will reach 25 and 30 from 2006 to 2008.

Judging from the latest data, the growth rate of chiral drugs in January and April has exceeded 50, and the new products have increased by 200%, and the company's valuation is significantly lower than the average level of the domestic pharmaceutical industry. We expect Winbond to have an annual P/E ratio of multiple and a "Beat Ratio" investment rating.

Meanwhile, Winbond was named one of the 16 most watched stocks by institutional investors last month. It is known as a hot stock in the cold industry. Therefore, it is recommended to hold shares in the medium term.

The above is from its own point of view, from a technical point of view, the stock is at a historical low, and the current stock price is only one or two cents away from the support level, so there is not much space, but there is a lot of space, so it is also recommended to hold shares in the medium term.

Monday's gap low opening is a foregone conclusion, it is recommended to be decisively out, and then there is a lower price, **in** when choosing the direction, there is no need to rush to intervene.

There is a certain selling pressure, the stock price is still low, and it can still be held.

It's really terrible, as the masters say, it's better to ask for someone than to ask for a few, and there will be anything to say, and it won't help you! Besides, there are many people with ulterior motives

It is recommended to sell it quickly, otherwise it will be killed If you don't know how to participate blindly, sooner or later you will kill yourself

Winbond Pharmaceutical's current market value is about 100 million yuan. Its market capitalization is calculated by multiplying the share price per share by the total share capital. It can be seen that the market value of Winbond Pharmaceutical is relatively strong.

1. Introduction of Winbond Pharmaceutical.

Winbond Pharmaceutical Co., Ltd. is a private joint-stock company located in Chongqing High-tech Industrial Development Zone. After more than ten years of development, it has now become a joint-stock high-tech Xinbang pharmaceutical enterprise with a registered capital of 100 million yuan, more than 600 employees and total assets of hundreds of millions of yuan. In March 2000, it was recognized as a national key high-tech enterprise by the Ministry of Science and Technology; In April of the same year, it became the first enterprise in Chongqing to pass the national GMP certification.

In April 2003, he was awarded the "National May Day Labor Award" by the All-China Federation of Trade Unions. Mr. Zhang Songshan, born in 1961, is a senior engineer with a doctorate degree, and is the core technical personnel of the company, and has been the chairman of the company since September 2001. This shows that the background of Winbond Pharmaceutical Company is relatively powerful, so its value must be very high.

Potato empty. 2. What is the treatment of Winbond Pharmaceutical?

Winbond Pharma pay depends on the position you want to work for. The position is different, and the treatment is definitely different. If you are applying for a sales position, the basic salary is about the same, depending on the individual's ability.

If you want to do medicine in this company, you must have at least 20,000 yuan of working capital and related funds in all aspects, which need to be prepared. If you complete the tasks assigned to you by the company, your annual bonus will be 48,000 yuan. Therefore, the treatment of Winbond Pharmaceutical is still good, especially after determining the position, if you are assigned to a good market, then your bonus income will definitely be higher imitation chain.

In addition, Winbond Pharmaceutical's ranking in the related industry can be regarded as above average, so if you have an idea, you can give it a try.

To sum up, the market value of Winbond Pharmaceutical is still very high, and the development has been very good, it is a private joint-stock company, the chairman's degree and background are very powerful, especially the treatment of Winbond Pharmaceutical is also very good, as long as the ability is strong, the treatment is very high.